Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
We have examined the effects of commonly used chemotherapeutic agents on human colon cancer cell lines in which the p53 pathway has been specifically disrupted by targeted homologous recombination. We found that p53 had profound effects on drug responses, and these effects varied dramatically depending on the drug. The p53-deficient cells were sensitized to the effects of DNA-damaging agents as a result of the failure to induce expression of the cyclin-dependent kinase inhibitor p21. In contrast, p53 disruption rendered cells strikingly resistant to the effects of the antimetabolite 5-fluorouracil (5-FU), the mainstay of adjuvant therapy for colorectal cancer. The effects on 5-FU sensitivity were observed both in vitro and in vivo, were independent of p21, and appeared to be the result of perturbations in RNA, rather than DNA, metabolism. These results have significant implications for future efforts to maximize therapeutic efficacy in patients with defined genetic alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some conventional chemotherapeutic drugs depend on the activation of p53 for their efficacy.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Comparing p53-proficient and -deficient HCT116 cells, such a dependency was found in particular for 5-fluorouracil (5-FU)44.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“A series of clinical studies have confirmed that CRC patients with wild-type P53 can benefit from 5-FU, and CRC patients with mutant P53 have a poor prognosis when receiving adjuvant chemotherapy [258,259,260].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [259]
In the citing paper
“On the other hand, the same report showed that p53-deficient cells displayed a higher sensitivity towards topoisomerase inhibitors such as Adriamycin.”
From CDK4 inhibition diminishes p53 activation by MDM2 antagonists (2018) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 4×
“We attribute this difference to the small amount of p53independent p21 induction following DNA damage that occurs after adriamycin treatment of p53-deficient cells (not shown), similar to that observed after γ-irradiation (14).”
BackgroundMethodInfluentialSelf-citationA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Self-citationKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 1×
“Introduction The p53 gene is inactivated in the majority of human cancers, resulting in profound effects on cell birth and death processes (1, 2).”
BackgroundMice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469 · cited 1×
“with mouse cells, for example, have provided unequivocal evidence of drug resistance after p53 inactivation (9, 10), but the extrapolation of these results to humans is far from straightforward.”
BackgroundApoptosis in cancer therapy: Crossing the threshold
Fisher, D. E. (1994) · Cell · doi:10.1016/0092-8674(94)90518-5 · Cited by 1,315
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251 · cited 1×
“The checkpoint function of p53 is mediated by the genes it transcriptionally regulates, including p21 (14, 15, 16) and 14-3-3σ (28), and keeps cells from progressing from G1 to S or G2 to M after DNA damage.”
BackgroundSelf-citationRadiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242
Research works printed but not linked: 6
- Hawkins, 1996, Cancer Res, 56, 892
- O’Connor, 1997, Cancer Res, 57, 4285
- Waldman, 1995, Cancer Res, 55, 5187
- Geoffroy, 1994, Oncol Res, 6, 581
- Wyllie, 1997, Eur J Cell Biol, 73, 189
- Cory, 1979, Cancer Res, 39, 4905
Cited by
Items 601–700 of 1,000
Xu, X., Tsang, S. W., Guan, Y.-F., Liu, K., Pan, W.-H., Lam, C. S., Lee, K. M., Xia, Y.-X., Xie, W.-J., Wong, W., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01742 · Cited by 27
Arnold, C., Demuth, P., Seiwert, N., Wittmann, S., Boengler, K., Rasenberger, B., Christmann, M., Huber, M., Brunner, T., Linnebacher, M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0393 · Cited by 30
“This is an important finding, because p53 mutations occur frequently in human cancer cells and affect their sensitivity toward DNAdamaging chemotherapeutics, as illustrated by an increased resistance of p53-deficient colorectal cancer cells to 5-FU (30, 40).”
BackgroundAl-Salihi, M. A., Yu, M. K., Burnett, D. M., Alexander, A., Samlowski, W. E., & Fitzpatrick, F. A. (2011) · Epigenetics · doi:10.4161/epi.6.8.16064 · Cited by 29
Xu, H., Yu, J., Sun, Y., Xu, X., Li, L., Xue, M., & Du, G. (2013) · Phytomedicine · doi:10.1016/j.phymed.2013.03.025 · Cited by 27
A personalized microRNA microarray normalization method using a logistic regression model
Wang, B., Wang, X., Howell, P., Qian, X., Huang, K., Riker, A. I., Ju, J., & Xi, Y. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp655 · Cited by 28
“The HCT-116 (wt-p53) and HCT-116 (null-p53) cell lines were a gift from Dr Bert Vogelstein at The Johns Hopkins University (Baltimore, MD, USA) and were described in detail previously (Bunz et al., 1998, 1999).”
MethodSCF(FBXW7)‐mediated degradation of p53 promotes cell recovery after UV‐induced DNA damage
Galindo‐Moreno, M., Giráldez, S., Limón‐Mortés, M. C., Belmonte‐Fernández, A., Reed, S. I., Sáez, C., Japón, M. Á., Tortolero, M., & Romero, F. (2019) · The FASEB Journal · doi:10.1096/fj.201900885r · Cited by 27
Maduro, J. H., de Vries, E. G. E., Meersma, G.-J., Hougardy, B. M. T., van der Zee, A. G. J., & de Jong, S. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.06.1902 · Cited by 29
A novel method for the combined flow cytometric analysis of cell cycle and cytochrome c release
Mohr, A., Zwacka, R. M., Debatin, K., & Stahnke, K. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401480 · Cited by 27
Defects in G1‐S cell cycle control in head and neck cancer: A review
Michalides, R. J. A. M., van den Brekel, M. W. M., & Balm, F. J. M. (2002) · Head & Neck · doi:10.1002/hed.10109 · Cited by 31
Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells
Bataller, M., Méndez, C., Salas, J. A., & Portugal, J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0420 · Cited by 30
“To gain new insights into the effects of p53 down-regulation by DNA-binding drugs, here we used isogenic HCT-116 colon carcinoma cells that differ only in the presence/absence of wild-type p53 alleles (17, 18).”
MethodGeller, J. I., Szücs, K. S., Peták, I., Doyle, B. T., & Houghton, J. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0863 · Cited by 27
“onstrated that neither doxorubicin nor etoposide induce preferential cytotoxicity in p21 / cells, determined in clonogenic survival assays, in contrast to apoptosis assays (27).”
BackgroundDifferential apoptosis by gallotannin in human colon cancer cells with distinct p53 status
Al‐Ayyoubi, S., & Gali‐Muhtasib, H. U. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20252 · Cited by 30
“the p53 gene to analyze the contribution of p53 to the response of tumor cells to GT treatment [34].”
BackgroundKoyama, F., SAWADA, H., Fujii, H., Hamada, H., Hirao, T., Ueno, M., & Nakano, H. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00338-5 · Cited by 27
“5-FUTP is incorporated into RNA (F-RNA), resulting in RNA dysfunction [3].”
BackgroundThames, H. D., Petersen, C., Petersen, S., Nieder, C., & Baumann, M. A. (2002) · Strahlentherapie und Onkologie · doi:10.1007/s00066-002-0923-x · Cited by 27
“A further complication is that widely used drugs such as 5-fluorouracil and adriamycin may provoke different responses [10, 24, 51].”
BackgroundXavier, C. P. R., Lima, C. F., Fernandes‐Ferreira, M., & Pereira‐Wilson, C. (2012) · Food & Function · doi:10.1039/c2fo10226a · Cited by 27
Lim, M., Ahn, J., Han, Y., Yu, C., Kim, M., Lee, S., Lim, D., & Song, J. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.04.022 · Cited by 26
5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53
Akpinar, B., Bracht, E. V., Reijnders, D., Šafaříková, B., Jelínková, I., Grandien, A., Vaculová, A. H., Zhivotovsky, B., & Olsson, M. (2015) · Oncotarget · doi:10.18632/oncotarget.6030 · Cited by 26
“Nevertheless, in experimental models where p53 status has been used to explain gross differences in 5-FU responses, it is evidently clear that cells harboring p53-insufficiency are also affected by treatment [9, 12].”
BackgroundResultLoss of Uracil DNA Glycosylase Selectively Resensitizes p53-Mutant and -Deficient Cells to 5-FdU
Yan, Y., Qing, Y., Pink, J. J., & Gerson, S. L. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0215 · Cited by 30
“For example, a study using isogenic cell systems demonstrated that deletion of p53 from a p53 WT colon cancer cell line (HCT116) rendered cells remarkably resistant to apoptosis induced by 5-FU (29).”
BackgroundAntoniali, G., Marcuzzi, F., Casarano, E., & Tell, G. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.08.007 · Cited by 27
p53 regulates LIF expression in human medulloblastoma cells
Baxter, E. W., & Milner, J. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0043-x · Cited by 26
“The HCT116 isogenic p53-/- and p53?/? clones (derived from a human colorectal carcinoma) used in this study were a kind gift from Bert Vogelstein [ 27 ].”
MethodMolecular imaging of p53 signal pathway in lung cancer cell cycle arrest induced by cisplatin
Wang, S., Li, W., Xue, Z., Lu, Y., Narsinh, K. H., Fan, W., Li, X., Bu, Q., Wang, F., Liang, J., et al. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.21930 · Cited by 29
“The present study showed that the protein level of p53 was significantly higher in vitro and in vivo after cisplatin treatment, causing upregulation of the cyclin-dependent kinase inhibitor p21 [24,29], and resulting in cell cycle arrests at the S- and G2/ M-phases [30,31].”
BackgroundGenotype-dependent radiosensitivity: Clonogenic survival, apoptosis and cell-cycle redistribution
Williams, J. R., Zhang, Y., Zhou, H., Russell, J., Gridley, D. S., Koch, C. J., & Little, J. B. (2008) · International Journal of Radiation Biology · doi:10.1080/09553000701797021 · Cited by 26
“Our study system includes two isogenic cell lines one of which has been abrogated in the TP53 gene, inducing changes in cellular response to some anticancer agents, including changes in susceptibility to apoptosis (Bunz et al. 1999).”
BackgroundMethodSelf-citationResistance of mitochondrial p53 to dominant inhibition
Heyne, K., Schmitt, K., Mueller, D., Armbruester, V., Mestres, P., & Roemer, K. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-54 · Cited by 31
“Etoposide was chosen as the stressor because it induces primarily cell cycle arrest whereas 5FU induces primarily apoptosis in HCT116 cells [23,28].”
BackgroundResultInfluentialThe emergence of resistance to targeted cancer therapeutics
Mellinghoff, I. K., & Sawyers, C. L. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.5.603 · Cited by 26
“Second, many apoptotic responses are affected by the expression status of the tumor suppressor gene p53 [230-232], which is rapidly activated under situations of cellular stress and transcriptionally upregulates proapoptotic members of the intrinsic and extrinsic cell death pathway [233].”
BackgroundCyclin-dependent kinases as targets for cancer therapy
Shah, M. A., & Schwartz, G. K. (2003) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(03)21007-3 · Cited by 29
Khan, M. A., Khan, A. A., Dwivedi, V., Ahmad, M., Hakeem, S., & Owais, M. (2007) · Molecular Medicine · doi:10.2119/2007-00018.khan · Cited by 27
Nord, S., Alnæs, G. I. G., Hihn, B., Lingjærde, O. C., Liestøl, K., Tsalenko, A., Sørlie, T., Lønning, P. E., Børresen‐Dale, A., & Kristensen, V. N. (2008) · International Journal of Cancer · doi:10.1002/ijc.23541 · Cited by 25
“In vitro studies have shown that loss of TP53 function reduces cellular sensitivity to 5-FU.(2)”
BackgroundBrody, J. R., Hucl, T., Costantino, C. L., Eshleman, J. R., Gallmeier, E., Zhu, H., van der Heijden, M. S., Winter, J. M., Wikiewicz, A. K., Yeo, C. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3610 · Cited by 25
“/ p53 cells when testing lower, clinically relevant 5-FU concentrations (19).”
InfluentialNET23/STING Promotes Chromatin Compaction from the Nuclear Envelope
Malik, P. R., Zuleger, N., Heras, J. I. D. L., Saiz-Ros, N., Makarov, A. A., Lazou, V., Meinke, P., Waterfall, M., Kelly, D. A., & Schirmer, E. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111851 · Cited by 31
“Cell culture, generation of stable lines, transfection and HSV-1 virus infection HeLa cells stably transfected with H2B-GFP ([72]), HT1080 human fibrosarcoma cells (ATCC, CCL-121), MRC5 normal human fetal lung fibroblasts (ATCC, CCL-171), 2162/2 lamin A knockout mouse embryonic fibroblasts [73], U2OS human bone osteos…”
MethodInfluentialHIF-1α contributes to tumour-selective killing by the sigma receptor antagonist rimcazole
Achison, M., Boylan, M. T., Hupp, T. R., & Spruce, B. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209890 · Cited by 26
“In an attempt to determine the possible contribution of the p53 pathway to the rimcazole-induced HIF-1a response, we compared isogenic strains of HCT-116 cells that differ only in p53 status (p53þ /þ vs p53 / ) (Bunz et al., 1999).”
BackgroundMethodDoxazolidine Induction of Apoptosis by a Topoisomerase II Independent Mechanism
Kalet, B. T., McBryde, M., Espinosa, J. M., & Koch, T. H. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070569b · Cited by 25
Okishiro, M., Kim, S. J., Tsunashima, R., Nakayama, T., Shimazu, K., Shimomura, A., Maruyama, N., Tamaki, Y., & Noguchi, S. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1637-5 · Cited by 25
PIK3CAandTP53mutations predict overall survival of stage II/III colorectal cancer patients
Li, A., Li, H., Tang, E., Wu, W., Chen, Y., Jiang, H., Lin, M., & Yin, L. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i5.631 · Cited by 31
Schweighoffer, F., Aı̈t-Ikhlef, A., Resink, A., Brinkman, B. M. N., Melle-Milovanovic, D., Laurent‐Puig, P., Kearsey, J., & Bracco, L. P. (2000) · Pharmacogenomics · doi:10.1517/14622416.1.2.187 · Cited by 25
Pharmacogenetics of neoplastic diseases: new trends
Paolo, A. D., Danesi, R., & Tacca, M. D. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.05.002 · Cited by 31
TAF15 contributes to the radiation-inducible stress response in cancer
Singh, A. K., Kapoor, V., Thotala, D. K., & Hallahan, D. E. (2020) · Oncotarget · doi:10.18632/oncotarget.27663 · Cited by 26
A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells
Song, J., Yu, J., Jeong, L. S., & Lee, S. K. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.003 · Cited by 25
Macha, S. J., Koneru, B., Burrow, T. A., Zhu, C., Savitski, D., Rahman, R. L., Ronaghan, C. A., Nance, J., McCoy, K., Eslinger, C. R., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0125 · Cited by 28
Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53
Warnock, L. J., Raines, S. A., & Milner, J. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.12.18141 · Cited by 26
Transcriptional inhibitors, p53 and apoptosis
Gartel, A. L. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.04.004 · Cited by 26
The tumor suppressor p53 connects ribosome biogenesis to cell cycle control: a double-edged sword
Hölzel, M., Burger, K., Mühl, B., Orban, M., Kellner, M., & Eick, D. (2010) · Oncotarget · doi:10.18632/oncotarget.107 · Cited by 29
“Consistently, adding an excess of uridine to 5-FU treated cells to specifically restore the RNA metabolism also abrogated p53 accumulation [7].”
BackgroundKorfali, N., Sršeň, V., Waterfall, M., Batrakou, D. G., Pekovic‐Vaughan, V., Hutchison, C. J., & Schirmer, E. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018762 · Cited by 26
“Vogelstein, Johns Hopkins University; [46]) cells were maintained in high glucose DMEM (Invitrogen) supplemented Figure 10.”
MethodKinzel, L., Ernst, A., Orth, M., Albrecht, V. S., Hennel, R., Brix, N., Frey, B., Gaipl, U. S., Zuchtriegel, G., Reichel, C. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9774 · Cited by 29
“To clarify whether this also applies to NW457-mediated apoptosis induction and radiosensitization, two previously described HCT116 subclones were employed which are deficient in p53 or Bax, respectively [41, 42].”
MethodImproved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations
Dominijanni, A. J., & Gmeiner, W. H. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.01 · Cited by 24
“At a molecular level, cellular response to 5-FU is TP53-dependent[9].”
BackgroundGil, H.-N., Jung, E., Koh, D., Lim, Y., Lee, Y. H., & Shin, S. Y. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.11.003 · Cited by 24
Tassi, E., & Wellstein, A. (2006) · Cancer Research and Treatment · doi:10.4143/crt.2006.38.4.189 · Cited by 28
Apoptosis induction by Epican Forte in HTLV-1 positive and negative malignant T-cells
Harakeh, S., Diab‐Assaf, M., Niedzwiecki, A., Khalife, J., Abu-El-Ardat, K., & Rath, M. (2006) · Leukemia Research · doi:10.1016/j.leukres.2005.11.027 · Cited by 25
Yoshida, K., Hamai, Y., Suzuki, T., Sanada, Y., Oue, N., & Yasui, W. (2006) · PubMed · Cited by 24
Hightower, M., Klem, J., Lee, D., Chu, E., Copur, S. M., & Jain, V. K. (2003) · Clinical Colorectal Cancer · doi:10.1016/s1533-0028(11)70462-5 · Cited by 24
p53 mutations are rare events in recurrent cervical cancer
Denk, C., Butz, K., Schneider, A., Dürst, M., & Hoppe‐Seyler, F. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100191 · Cited by 24
“However, this issue is likely to be much more complex than initially presumed since there is also recent experimental evidence that mtp53 is also associated with increased sensitivity to genotoxic agents, depending on the genetic background of the tumor and the therapeutic agent used [14].”
BackgroundDNA damage-induced apoptosis: insights from the mouse
Zabkiewicz, J., & Clarke, A. R. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2004.09.002 · Cited by 26
“p53 null tumour cells have also been reported to be extremely resistant to 5FU-induced damage [40].”
Can multidrug resistance mechanisms be modified?
Arceci, R. J. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02063.x · Cited by 24
“In fact, other studies have shown that colon cancer cells engineered to lack functional p53 may develop resistance to some cytotoxic agents but may become more sensitive to other agents, including radiation (Bunz et al, 1999).”
BackgroundTp53 gene therapy: a key to modulating resistance to anticancer therapies?
Chang, E. H., Pirollo, K. F., & Bouker, K. B. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01767-6 · Cited by 24
Harmonized microarray/mutation scanning analysis of TP53 mutations in undissected colorectal tumors
Favis, R., Huang, J., Gerry, N. P., Culliford, A. T., Paty, P. B., Soussi, T., & Barany, F. (2004) · Human Mutation · doi:10.1002/humu.20069 · Cited by 25
“For example, the commonly used cancer drug, 50-fluorouracil, is ineffective in TP53deficient human cells; however, the DNA damaging agent, adriamycin, induces apoptosis irrespective of the TP53 status [Bunz et al., 1999].”
BackgroundThottassery, J. V., Westbrook, L., Someya, H., & Parker, W. B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0409 · Cited by 29
“The p53 / HCT 116 line, however, is an isogenic line where p53 has been deleted by homologous recombination which can be used to assess whether the induction of p53 is essential in the apoptotic/cytotoxic effects of these drugs (14).”
BackgroundZargar, P., Ghani, E., Mashayekhi, F., Ramezani, A., & Eftekhar, E. (2018) · Oncology Letters · doi:10.3892/ol.2018.8569 · Cited by 23
García, M. Á., Marchal, J. A., Carrasco, E., Ramírez, A., Jiménez, G., Olmedo, C., Perán, M., Agil, A., Conejo‐García, A., Cruz‐López, O., et al. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s51354 · Cited by 30
Gomes, N. P., & Espinosa, J. M. (2010) · Cell Cycle · doi:10.4161/cc.9.17.12998 · Cited by 24
“The effects of this pleiotropy are manifested in the clinic, where activation of p53 by genotoxic stress leads to cancer cell death and tumor regression only in a fraction of cases.(3-9) Conversely, systemic activation of p53 causes many of the undesirable side effects of genotoxic therapies by triggering apoptosis in…”
BackgroundUsing targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity
Goh, A. M., Lim, C. Y., Chiam, P. C., Li, L., Mann, M. B., Mann, K. M., Ménendez, S., & Lane, D. P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114173109 · Cited by 25
“Given that p53 target gene selection is stimulus-specific (24), we tested whether our reporter system could detect differences in p53 transcriptional activity upon treatment with different genotoxic agents.”
Backgroundp73 and MDM2 confer the resistance of epidermoid carcinoma to cisplatin by blocking p53
Hayashi, S., Ozaki, T., Yoshida, K., Hosoda, M., Todo, S., Akiyama, S., & Nakagawara, A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.095 · Cited by 24
Heyne, K., Willnecker, V., Schneider, J., Conrad, M., Raulf, N., Schüle, R., & Roemer, K. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq016 · Cited by 27
“However, NIR could also function to specifically inhibit target genes such as p21 that are known to suppress apoptosis (39,40), and thereby support an apoptotic response if necessary.”
BackgroundHu, C., & Chang, Z.-F. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3069 · Cited by 23
“In particular, the loss of p53 function (due to its high frequency of mutation) decreases the 5-FU responsiveness in cancer cells (14, 15).”
BackgroundLi, X., Li, B., Ni, Z., Zhou, P., Wang, B., He, J., Xiong, H., Yang, F., Wu, Y., Lyu, X., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0763 · Cited by 24
“Thenet effects reinforce the paradoxical phenotype that p53 predominantly functions as a tumor suppressor, but in specific conditions, it can render cancer cells resistant to chemotherapy (48, 49).”
BackgroundSelf-citationXu, J., Yan, B., Du, X., Xiong, J., Zhou, M., Wang, H., & Du, Z. (2019) · Polymer Chemistry · doi:10.1039/c8py01518j · Cited by 24
8-Cl-Adenosine-Induced Inhibition of Colorectal Cancer Growth In Vitro and In Vivo
Carlson, C. C., Chinery, R., Burnham, L. L., & Dransfield, D. T. (2000) · Neoplasia · doi:10.1038/sj.neo.7900106 · Cited by 23
Mitsunaga, M., Tsubota, A., Nariai, K., Namiki, Y., Sumi, M., Yoshikawa, T., & Fujise, K. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i5.692 · Cited by 24
Menendez, D., Anand, J. R., Murphy, C. C., Bell, W. J., Fu, J., Slepushkina, N., Buehler, E., Martin, S. E., Lal-Nag, M., Nitiss, J. L., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28195 · Cited by 22
“Functional status of p53 markedly impacts the sensitivity of cancer cells to a variety of chemotherapeutic agents by diverse mechanisms [39].”
BackgroundAghabozorgi, A. S., Sarabi, M. M., Esfehani, R. J., Koochakkhani, S., Hassanzadeh, M., Kavousipour, S., & Eftekhar, E. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i9.942 · Cited by 24
Mechanism of apoptosis activation by Curcumin rescued mutant p53Y220C in human pancreatic cancer
Malhotra, L., Sharma, S., Hariprasad, G., Dhingra, R., Mishra, V., Sharma, R. S., Kaur, P., & Ethayathulla, A. S. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119343 · Cited by 25
Ludikhuize, M. C., Gevers, S., Nguyen, N. B., Meerlo, M., Roudbari, S. K. S., Gülersönmez, M. C., Stigter, E. C. A., Drost, J., Clevers, H. C., Burgering, B. M. T., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04055-8 · Cited by 24
Structure-Function Analysis of the Mcl-1 Protein Identifies a Novel Senescence-regulating Domain
Demelash, A., Pfannenstiel, L. W., Tannenbaum, C. S., Li, X., Kalady, M. F., DeVecchio, J., & Gastman, B. R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.663898 · Cited by 27
Lupi, M., Matera, G., Natoli, C., Colombo, V., & Ubezio, P. (2007) · Cell Cycle · doi:10.4161/cc.6.8.4103 · Cited by 23
Survival of distinct Asian groups among colorectal cancer cases in California
Le, H. V., Ziogas, A., Taylor, T. H., Lipkin, S. M., & Zell, J. A. (2008) · Cancer · doi:10.1002/cncr.24034 · Cited by 22
“In addition, a previous in vitro study observed that proximal tumors more often had wild-type TP53, and that disruption of TP53 caused CRC cells to become resistant to 5-FU.(30) Another consideration is the possibility that certain Asian subset groups may respond better to other agents such as oxaliplatin or irinoteca…”
BackgroundJin, H. R., Du, C. H., Wang, C., Yuan, C., & Du, W. (2018) · Phytotherapy Research · doi:10.1002/ptr.6249 · Cited by 22
“The p53−/−HCT116 cells were described previously (Bunz et al., 1999; Li et al., 2011).”
BackgroundThomas, L. W., Stephen, J. M., Esposito, C., Hoer, S., Antrobus, R., Ahmed, A., Al-Habib, H., & Ashcroft, M. A. (2019) · Cancer & Metabolism · doi:10.1186/s40170-019-0194-y · Cited by 25
“Human U2OS-HRE-luc [16] or human HCT116 colon carcinoma cells [17] were used to stably express two independent shRNA control vectors (Empty Vector (shRNA control 1) and GFP Vector (shRNA control 2)) or two independent shRNAs targeting CHCHD4 (CHCHD4 shRNA1 or CHCHD4 shRNA2) utilizing a green fluorescent protein (GFP)-…”
MethodCyclin dependent kinases as targets for cancer therapy
Shah, M. A., & Schwartz, G. K. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.08.001 · Cited by 24
Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53
Mann, K., & Hainaut, P. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208563 · Cited by 24
“It is known that the DNA-damaging agents adriamycin and etoposide induce apoptosis in HCT116p53 / cells and HCT116p21 / cells, while HCT116p53þ /þ cells do not undergo apoptosis (Waldman et al., 1996; Bunz et al., 1999).”
BackgroundKlug, C., Keszthelyi, D., Ploder, O., Sulzbacher, I., Voracek, M., Wagner, A., Millesi, W., Kornek, G., Kainberger, F. M., Kermer, C., et al. (2004) · Head & Neck · doi:10.1002/hed.10373 · Cited by 22
TIF-IA: An oncogenic target of pre-ribosomal RNA synthesis
Jin, R., & Zhou, W. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.003 · Cited by 30
Cascinu, S., Catalano, V., Aschele, C., Barni, S., Debernardis, D., Gallo, L., Bandelloni, R., Staccioli, M. P., Baldelli, A. M., Brenna, A., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008362511552 · Cited by 22
Farrington, S. M., & Dunlop, M. G. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511543555.018 · Cited by 22
Translational Regulation as a Novel Mechanism for the Development of Cellular Drug Resistance
Schmitz, J. C., Liu, J., Lin, X., Chen, T.-M., Wu, Y., Tai, N., Gollerkeri, A. M., & Chu, E. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013100306315 · Cited by 22
Cole, S. L., & Tevethia, M. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.16.8420-8432.2002 · Cited by 22
“Targeted disruption of the p53 gene in these cells prevents 5-FU-induced apoptosis (7).”
BackgroundAgomelatine, a Melatonin-Derived Drug, as a New Strategy for the Treatment of Colorectal Cancer
Moreno-SanJuan, S., Puentes-Pardo, J. D., Casado, J., Escudero-Feliú, J., Khaldy, H., Arnedo, J., Carazo, Á., & León, J. (2023) · Antioxidants · doi:10.3390/antiox12040926 · Cited by 27
“Similarly to melatonin, several lines of research demonstrated that this chemotherapeutic agent has a reduced ability to inhibit cell growth in CRC with mutated or inactive p53 [57].”
BackgroundDamnjanović, I., Kocic, G. M., Najman, S. J., Stojanović, S., Stojanović, D. B., Veljković, A., Conić, I., Langerholc, T., & Pesic, S. (2014) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2014_118 · Cited by 21
“Another way of resistance can be explained by a decreased transport of nucleosides and nucleobases in cells by nucleoside / nucleobase transporters (19), while some authors have found that the p53 status and DNA defects recovery may be important resistance causes (20).”
Williams, D. S., Mouradov, D., Browne, C., Palmieri, M., Elliott, M. J., Nightingale, R., Fang, C. G., Li, R., Mariadason, J. M., Faragher, I. G., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0353-2 · Cited by 24
Nobili, S., Napoli, C., Landini, I., Morganti, M., Cianchi, F., Valanzano, R., Tonelli, F., Cortesini, C., Mazzei, T., & Mini, E. (2010) · International Journal of Cancer · doi:10.1002/ijc.25514 · Cited by 21
“Mutations in TP53 or disruption through homologous recombination of TP53 in colorectal cancer cells are related to resistance to 5-FU and lack of sensitization to 5-FUinduced Fas-mediated apoptosis.(31,32) TP53 has been investigated as a predictive factor of colorectal cancer response to therapy with conflicting resul…”
ResultTRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond
Wu, Q., Nandi, D., & Sharma, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10226-2 · Cited by 25
Kraljević, T. G., Ilić, N., Stepanić, V., Sappe, L., Petranović, J., Pavelić, S. K., & Raić‐Malić, S. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.04.079 · Cited by 20
Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective
Manne, U., Jadhav, T., Putcha, B. K., Samuel, T., Soni, S., Shanmugam, C., & Suswam, E. A. (2016) · Current Colorectal Cancer Reports · doi:10.1007/s11888-016-0338-1 · Cited by 21
Grothey, A. F., Yoshino, T., Bodoky, G., Ciuleanu, T., García‐Carbonero, R., Alfonso, P. G., Cutsem, E. V., Muro, K., Mytelka, D. S., Li, L., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000347 · Cited by 22
Stravopodis, D. J., Karkoulis, P. K., Konstantakou, E. G., Melachroinou, S., Thanasopoulou, A., Aravantinos, G., Margaritis, L. H., Anastasiadou, E., & Voutsinas, G. E. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0891-y · Cited by 23
“rendered colon cancer cells resistant to 5-FU exposure, both in vitro and in vivo (Adamsen et al. 2007; Bunz et al. 1999).”
BackgroundMealey, K. L., Bentjen, S. A., Gay, J. M., & Hosick, H. L. (2003) · Veterinary and Comparative Oncology · doi:10.1046/j.1476-5829.2003.00009.x · Cited by 20
“Ongoing research in yeast, Dictyostelium discoideum, and hamster cells has identified several candidate genes that appear to play a role in cisplatin resistance (Eliopoulos et al., 1995; Bunz et al., 1999; Yin et al., 2000).”
BackgroundThe p53 Tumor Suppressor Pathway and Cancer
Zambetti, G. P. (2005) · Springer eBooks · doi:10.1007/0-387-30127-5 · Cited by 24
Oncogenes and Tumor Angiogenesis
Rak, J. W., & Kerbel, R. S. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-313-2_10 · Cited by 21
Thurner, E.-M., Krenn-Pilko, S., Langsenlehner, U., Renner, W., Gerger, A., Kapp, K. S., & Langsenlehner, T. (2014) · Strahlentherapie und Onkologie · doi:10.1007/s00066-013-0485-0 · Cited by 20
Release of Cytochrome c from Isolated Mitochondria by Etoposide
Park, J., & Kim, T. (2005) · BMB Reports · doi:10.5483/bmbrep.2005.38.5.619 · Cited by 19
“For example, tumor cells expressing p53 wild type protein are extremely susceptible to the induction of cell death by various chemotherapeutic agents such as 5'-fluoro-uracil (5'-FU), whereas various tumor cells having mutation in p53 are resistant to drug-induced cell death (Lowe et al., 1993b; Lowe et al., 1994; Bun…”
BackgroundMethodInfluentialTargeting Protein Tyrosine Kinase 6 Enhances Apoptosis of Colon Cancer Cells following DNA Damage
Gierut, J. J., Mathur, P., Bie, W., Han, J., & Tyner, A. L. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0009 · Cited by 23
“Mutation or deletion of p53 has been shown to lead to resistance of cells to 5FU (19, 27).”
Application of CRISPR-mediated genome engineering in cancer research
Sayin, V. I., & Papagiannakopoulos, T. Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.029 · Cited by 22
Fukushi, S., Yoshino, H., Yoshizawa, A., & Kashiwakura, I. (2016) · BMC Cancer · doi:10.1186/s12885-016-2585-6 · Cited by 20
“The importance of p53 in cancer treatment has been shown in many studies [8–11].”
Background
Metadata
- Authors
- Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Georgetown University (US)
- Johns Hopkins University (US)
- Corresponding author
- Vogelstein, Bert
- Venue
- Journal of Clinical Investigation
- Published
- 1999-08-01
- Volume
- 104
- Issue
- 3
- Pages
- 263-269
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC408422
- OpenAlex
- W1982097971
- Cited by
- 1,044
- References
- 33
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 17 · 2023: 26 · 2022: 23 · 2021: 19 · 2020: 27 · 2019: 26 · 2018: 25 · 2017: 24 · 2016: 36 · 2015: 32 · 2014: 35 · 2013: 43 · 2012: 38
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Foundation for Cancer Research
- Johns Hopkins University
- National Institutes of Health
- National Cancer Institute (CA 57345, R01CA057345, P50CA062924, R37CA057345, CA 62924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, p53 deficiency, chemoresistance, 5-fluorouracil, antimetabolite resistance, p21, cyclin-dependent kinase inhibitors, DNA-damaging agents, chemosensitization, colon cancer, colorectal cancer, RNA metabolism, drug response
- MeSH terms
- Animals, Antineoplastic Agents, Colonic Neoplasms, DNA Damage, Doxorubicin, Fluorouracil, Humans, Mice, Nude, Neoplasm Transplantation, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Gene Deletion, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase Inhibitor p21, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.